Becton Dickinson Option Alert: Fri $245 Puts at the Ask: 800 vs 3100 OI

Becton Dickinson Option Alert: Fri $245 Puts at the Ask: 800 @ $20.4 vs 3100 OI; Ref=$225.13

Becton Dickinson Option Alert: Fri $240 Puts at the Bid: 800 vs 3579 OI

Becton Dickinson Option Alert: Fri $240 Puts at the Bid: 800 @ $15.4 vs 3579 OI; Ref=$225.13

Becton Dickinson (NYSE:BDX) Azioni

Becton Dickinson

Becton, Dickinson

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.

AMZN

HOLX

ORCL

Con l&#39;ottimismo che pervade Wall Street, alcuni titoli mostrano promettenti segnali di crescita per l&#39;ultima settimana di gennaio.

5 azioni dell&#39;S&amp;P 500 che potrebbero decollare a fine gennaio

Becton, Dickinson and Company Common Stock

Becton Dickinson & Co

These large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) shares tumbled 19.90% after the company reported <a href="https://www.benzinga.com//node/45152696" target="_blank" rel="noreferrer noopener">worse-than-expected financial results</a>. Analysts slashed <a href="https://www.benzinga.com/quote/xyz/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Lineage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) shares fell 18.93% after reporting worse-than-expected <a href="https://www.benzinga.com//node/45093641" target="_blank" rel="noreferrer noopener">first-quarter sales results</a>. Some analysts lowered the <a href="https://www.benzinga.com/quote/line/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) stock dipped 17.70%  after the company cut FY25 EPS guidance despite a hike in sales outlook. The company also missed <a href="https://www.benzinga.com//node/45140102" target="_blank" rel="noreferrer noopener">second-quarter revenue estimates</a>. Analysts cut <a href="https://www.benzinga.com/quote/bdx/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Coca-Cola (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>) shares decreased 16.36%  after the company reported a year-over-year decrease in <a href="https://www.benzinga.com//node/45116927" target="_blank" rel="noreferrer noopener">first-quarter financial results</a>.</li>
<li>Westlake Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) stock fell 14.50% after the company reported worse-than-expected <a href="https://www.benzinga.com//node/45161312" target="_blank" rel="noreferrer noopener">first-quarter sales results</a>.</li>
<li>Pilgrim&#8217;s Pride Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPC#NASDAQ">PPC</a>) stock dived 13.84% after the company reported worse-than-expected <a href="https://www.benzinga.com//node/45118399" target="_blank" rel="noreferrer noopener">first-quarter financial results</a>.</li>
<li>Ecopetrol S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) shares declined 12.27% probably amid a drop in oil and natural gas prices following a decline in U.S. first-quarter GDP, which could weigh on demand outlook.</li>
<li>Alamos Gold Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGI#NYSE">AGI</a>) shares were down 11.59% after the company reported <a href="https://www.benzinga.com//node/45119634" target="_blank" rel="noreferrer noopener">first-quarter results below estimates</a>. The stock may also be down amid a drop in gold spot price.</li>
<li>YPF Sociedad Anonima (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YPF#NYSE">YPF</a>) stock fell 9.09%.</li>
<li>Targa Resources, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) stock dived 8.87% after the company reported <a href="https://www.benzinga.com//node/45128247" target="_blank" rel="noreferrer noopener">earnings for the first quarter</a>.</li>
</ol>
Photo via Shutterstock

Equities

Large Cap

News

Movers

Trading Ideas

COKE

FSLR

LINE

TRGP

Block, Becton Dickinson And Pilgrim's Pride Are Among Top 10 Large-Cap Losers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?

Becton Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) lowered its fiscal year 2025 guidance and provided an <a href="https://www.benzinga.com/pressreleases/25/05/n45128945/bd-reports-second-quarter-fiscal-2025-financial-results" target="_blank" rel="noreferrer noopener">estimated tariff impact </a>on Thursday.
The medical device company reported adjusted earnings per share of $3.35, up from $3.17 a year ago. It beat the <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">consensus of $3.28</a>.
The company reported first-quarter 2025 sales of $5.27 billion, up 4.5% year-over-year, missing the consensus of $5.35 billion.
Becton Dickinson expects fiscal 2025 revenues of $21.8 billion and $21.9 billion. Its previously issued guidance of $21.7 billion to $21.9 billion reflects updated organic revenue growth guidance of 3.0% to 3.5% and an improvement in the <a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">estimated impact of foreign currency</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43443889/starboard-value-pushes-becton-dickinson-to-divest-life-sciences-unit" rel="noreferrer noopener">Activist Starboard Value Pushes Becton Dickinson To Divest Life Sciences Unit</a>
Goldman Sachs on Friday downgraded Becton Dickinson from Buy to Neutral, revising its <a target="_blank" href="https://www.benzinga.com/quote/BDX/analyst-ratings" rel="noreferrer noopener">price target from $256 to $192</a>.
Analyst David Roman says BDX stock has fallen 25% since being added to the Buy list on May 30, 2024, compared to the S&amp;P500&#8217;s 6% and their large-cap MedTech coverage of 5%.
&#8220;We think the underperformance reflects downward revisions in organic growth estimates despite ongoing strong P&amp;L results. Specifically, the forward outlook for organic revenue growth has shifted from ~5-6% two years ago to ~3-4%. This level of organic growth puts BD at the low-end of MedTech,&#8221; Roman added.
Goldman Sachs says because Becton Dickinson has a large share of its market, its growth is closely tied to how fast the overall market is growing. As the market has slowed, so have Becton Dickinson&#8217;s growth targets.
Some of these market challenges may ease over time. But Roman is less confident that Becton will return to steady mid-single-digit organic revenue growth by fiscal year 2026 — a key part of the investment case.
William Blair on Thursday downgraded Becton Dickinson to Market Perform following a disappointing fiscal second-quarter update.
&#8220;We have been wrong with our rating on this stock for several years, holding out hope that shares would see multiple expansion once the business found a new gear that resulted in more predictable revenue growth, margin expansion, and earnings growth,&#8221; analyst Andrew Brackmann writes.
William Blair writes that Becton, at its core, has the makeup to drive mid-single-digit revenue growth over an extended period.
However, that is not the case right now, making the near-term setup challenging— especially as the Bioscience and Diagnostics business is set to be separated but for which those businesses are seeing increased headwinds.
The analyst seeks greater confidence in a reacceleration in organic growth and looks to fiscal 2026 guidance and updates on the Bioscience and Diagnostics separation as key catalysts over the coming months.
Stifel maintains Becton Dickinson with a Buy, lowering the price target from $280 to $224.
Piper Sandler downgrades Becton Dickinson from Overweight to Neutral and lowers the price target from $260 to $185.
Price Action: BDX stock is down 1.36% at $167.24 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/05/45171306/magna-shares-fall-as-profit-miss-overshadows-strong-sales-higher-outlook" target="_blank" rel="noreferrer noopener">Magna Shares Fall As Profit Miss Overshadows Strong Sales, Higher Outlook</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Guidance

Downgrades

Health Care

Price Target

Analyst Ratings

General

Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years

Wall Street extended its rally this week, fully erasing the losses suffered after the Trump administration's <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45172683/wall-street-eyes-9th-straight-day-of-gains-apple-falls-as-chinese-sales-disappoint-whats-driving-markets-friday">tariff announcement on April 2. </a>
Investor sentiment was buoyed by encouraging developments in trade negotiations and, most importantly, a stronger-than-expected start to earnings season.
Corporate America showed resilience in the face of trade headwinds. Mega-cap tech giants —including Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) — all surpassed Wall Street estimates, with Microsoft logging its best weekly performance in years.
The S&amp;P 500 posted its second consecutive weekly gain, marking its longest winning streak since May 2024.
Top individual performers included Arista Networks Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) and Carrier Global Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>), both soaring roughly 20% for the week. On the downside, Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) tumbled 20%, making it the worst performer.
Michigan-based automaker General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) topped earnings forecasts yet withdrew guidance for the year amid "massive <a href="https://www.benzinga.com/news/earnings/25/05/45150325/gm-cut-its-2025-forecast-on-tariffs-but-core-business-holds-up-says-goldman-sachs">uncertainty&#8221; over tariffs.</a>
From a sector perspective, industrials and technology led the charge, while energy stocks lagged as crude oil prices slumped. Oil marked its second-worst week of the year, falling to $58 per barrel after Saudi Arabia signaled its readiness to cope with lower prices, stoking speculation that OPEC+ may boost output further in the coming months.
President Donald Trump's threat to impose secondary sanctions on nations buying Iranian oil failed to stabilize crude <a href="https://www.benzinga.com/government/regulations/25/05/45149446/oil-prices-soar-after-trump-threatens-sanctions-on-iranian-crude-buyers-is-china-on-top-of-the-list">prices, which continued to slide</a>.
Macroeconomic data painted a mixed picture. First-quarter gross domestic product shrank by 0.3%, missing forecasts of a 0.4% rise, largely due to a surge in imports.
Yet, inflation and employment data provided a more positive outlook. Nonfarm payrolls rose by 177,000 in April, beating the 130,000 consensus and <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45164558/us-adds-177000-jobs-in-april-topping-forecasts-as-economy-navigates-tariff-impact">underscoring labor market strength.</a>
Meanwhile, Personal <a href="https://www.benzinga.com/25/04/45102421/feds-key-inflation-gauge-cools-before-tariffs-hit-auto-outlays-spike-as-consumers-front-run-price-impacts">Consumption </a><a href="https://www.benzinga.com/25/04/45102421/feds-key-inflation-gauge-cools-before-tariffs-hit-auto-outlays-spike-as-consumers-front-run-price-impacts" target="_blank" rel="noopener">Expenditure inflation cooled</a>: annual price gains slowed from 2.7% in February to 2.3% in March. Core PCE, the Federal Reserve's preferred inflation gauge, eased to 2.6% year over year, aligning with expectations and down from 3%.
Looking ahead, markets will focus on the Federal Reserve's two-day policy meeting starting Tuesday. While no rate change is anticipated, Chair Jerome Powell's Wednesday press conference will be closely watched, especially after renewed calls from President Trump <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45166673/trump-pressures-fed-after-solid-jobs-cooling-inflation-lower-rates-now">to cut interest rates.</a>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45173740/5-great-income-buys-for-the-coming-downturn">5 Great Income Buys For The Coming Downturn</a></li>
</ul>
Photo: Shutterstock

Government

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Commodities

Economics

Federal Reserve

Tech

ETFs

AAPL

ANET

CARR

MSFT

Wall Street Fully Recoups Tariff-Led Losses, Economy Contracts In First Quarter Yet April Payrolls Remain Strong: This Week In Markets

The U.S. stock market staged a stunning one-month rebound, fully erasing the losses triggered by Donald Trump&#8216;s <a href="https://www.benzinga.com/topic/donald-trump">April 2 tariff announcements.</a>
From its April low of 4,835 points, the S&amp;P 500—tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)—has surged 17.5%, logging nine consecutive sessions of gains through Friday, the longest winning streak since May 2024.
Still, the rally has been far from uniform across sectors.
The sectoral rebound since April has been powerful, but only a handful of sectors have managed to fully recover to or exceed their April 2 levels, before Trump&#8217;s tariff announcements triggered a broad selloff.
Technology led the charge, surging 25.9% since the April low and now stands 3.8% above its April 2 level, the strongest full recovery among all major sectors.
Industrials and Utilities also climbed 1.8% and 1% above their early-April levels, respectively.
Sectors like Consumer Discretionary , Communication Services, Financials, Consumer Staples, and Real Estate posted strong double-digit rebounds off April lows—ranging from 8.3% to 18.9%— finally reaching April 2 levels without breaching them.
On the other end of the spectrum, Energy remains 13.4% below its April 2 level, making it the worst laggard. Health Care is still down 4% from early April, even after recovering 7.2%. Materials also underperformed, ending the period 1.9% below its pre-tariff announcement level.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Sector</th>
<th>%chg since April lows</th>
<th>May 2 vs. April 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>16.1%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Consumer Staples&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>8.3%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>16.9%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>11.3%</td>
<td>-13.4%</td>
</tr>
<tr>
<td>Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>18.9%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Health Care&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>7.2%</td>
<td>-4%</td>
</tr>
<tr>
<td>Industrials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>20.4%</td>
<td>up by 1.8%</td>
</tr>
<tr>
<td>Materials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>16.4%</td>
<td>-1.9%</td>
</tr>
<tr>
<td>Real Estate&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>17.2%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>25.9%</td>
<td>up by 3.8%</td>
</tr>
<tr>
<td>Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>12.2%</td>
<td>up by 1%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Top Performing S&amp;P 500 Stocks Since April 2</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Sector</td>
<td>Return</td>
</tr>
<tr>
<td>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)</td>
<td>Information Technology</td>
<td>41.22%</td>
</tr>
<tr>
<td>Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)</td>
<td>Communication Services</td>
<td>23.45</td>
</tr>
<tr>
<td>Quanta Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>)</td>
<td>Industrials</td>
<td>23.16</td>
</tr>
<tr>
<td>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>)</td>
<td>Industrials</td>
<td>20.78</td>
</tr>
<tr>
<td>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</td>
<td>Information Technology</td>
<td>18.92</td>
</tr>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>Information Technology</td>
<td>18.87</td>
</tr>
<tr>
<td>ServiceNow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NASDAQ">NOW</a>)</td>
<td>Information Technology</td>
<td>18.80</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Worst Performer Since April 2</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Sector</td>
<td>Return</td>
</tr>
<tr>
<td>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>Information Technology</td>
<td>-26.66%</td>
</tr>
<tr>
<td>Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)</td>
<td>Health Care</td>
<td>-25.89</td>
</tr>
<tr>
<td>UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>Health Care</td>
<td>-23.76</td>
</tr>
<tr>
<td>APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</td>
<td>Energy</td>
<td>-21.40</td>
</tr>
<tr>
<td>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>)</td>
<td>Financials</td>
<td>-20.95</td>
</tr>
<tr>
<td>Targa Resources Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>)</td>
<td>Energy</td>
<td>-20.79</td>
</tr>
<tr>
<td>Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>)</td>
<td>Health Care</td>
<td>-20.00</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/05/45174409/nasdaq-100-leveraged-etf-tqqq-surges-55-as-tech-rally-jobs-data-boost-risk-appetite">Nasdaq-100 Leveraged ETF TQQQ Surges 5.5% As Tech Rally, Jobs Data Boost Risk Appetite</a></li>
</ul>
Photo: Shutterstock

Markets

AVGO

CRWD

ENPH

NFLX

PLTR

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street Roars Back From April Tariff Sell-Off: Which Sectors Are Still Underwater?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Rosenblatt analyst Barton Crockett downgraded the rating for Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from Buy to Neutral and lowered the price target from $263 to $217. Apple shares closed at $213.32 on Thursday. <a href="https://www.benzinga.com/quote/aapl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Jeff Cantwell downgraded the rating for Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) from Buy to Neutral. Block shares closed at $58.48 on Thursday. <a href="https://www.benzinga.com/quote/XYZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst Maher Yaghi downgraded Thomson Reuters Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRI#NASDAQ">TRI</a>) from Sector Outperform to Sector Perform and announced a price target of $188. Thomson Reuters shares closed at $185.74 on Thursday. <a href="https://www.benzinga.com/quote/TRI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Jason Bednar downgraded the rating for Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) from Overweight to Neutral and lowered the price target from $260 to $185. Becton Dickinson shares closed at $169.54 on Thursday. <a href="https://www.benzinga.com/quote/BDX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush analyst Scott Devitt downgraded Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from Outperform to Neutral and slashed the price target from $150 to $135. Airbnb shares closed at $124.01 on Thursday. <a href="https://www.benzinga.com/quote/ABNB/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02134834/image-26-1024x586.png" alt="" class="wp-image-899761" style="width:507px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02134834/image-26-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02134834/image-26-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02134834/image-26-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02134834/image-26.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45164963/how-to-earn-500-a-month-from-tyson-foods-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Tyson Foods Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

ABNB

This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

WIIM

Becton, Dickinson and Company shares are trading lower after Stifel maintained a Buy rating on the stock and lowered its price target from $280 to $224. Also, Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target from $260 to $185.

Piper Sandler analyst Jason Bednar downgrades Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) from Overweight to Neutral and lowers the price target from $260 to $185.

Piper Sandler Downgrades Becton Dickinson to Neutral, Lowers Price Target to $185

Stifel analyst Rick Wise maintains Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) with a Buy and lowers the price target from $280 to $224.

Stifel Maintains Buy on Becton Dickinson, Lowers Price Target to $224

Shares of Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) are coming back a little on Friday. This follows Thursday&#8217;s more than 18% drop.
There may have been a capitulation, which could be bullish for the stock. This is why our technical analysis team has made it our Stock of the Day.
The company reported earnings of $3.35 per share. This was ahead of consensus estimates of $3.28.
But the guidance is what brought in the sellers.
Concerning the tariffs, Becton said, &#8220;International trade policies, trade restrictions and tariffs are rapidly evolving and there can be no assurance as to how the landscape may change and what the ultimate impact on our guidance and results of operations will be.&#8221;
Read Also: <a href="https://www.benzinga.com/tech/25/05/45156890/apple-ceo-tim-cook-warns-of-900-million-tariff-impact-in-june-quarter-expects-majority-of-iphones-sold-in-us-to-be-made-in-india">Apple CEO Tim Cook Warns Of $900 Million Tariff Impact In June Quarter, Expects Majority Of iPhones Sold In US To Be Made In India</a>
Yesterday's trading may have been a capitulation; if so, the shares may move higher.
Capitulations occur when frustrated sellers stop worrying about what price they sell their shares for. They are tired of watching the price drop and make up their minds to sell regardless of where they are trading.
As a result, there was a huge volume of trades. You can see on the chart that this was the case on Thursday.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02094110/one-1-1024x593.png" alt="" class="wp-image-899171" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02094110/one-1-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02094110/one-1-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02094110/one-1-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02094110/one-1.png 1417w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
This could have bullish implications.
If all investors and traders who wanted to sell have done so, those who wish to buy will have no choice but to be willing to pay successively higher prices if they want to draw sellers back into the market. This could push the stock into an uptrend.
Many traders overcomplicate things. They forget that markets are driven by supply and demand. If there is more demand than supply, they move higher. If there is more supply than demand, they trend lower.
If a market runs out of supply, the only way that it can go is up. This may be about to happen with shares of Becton, Dickenson.
Read Next: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45164558/us-adds-177000-jobs-in-april-topping-forecasts-as-economy-navigates-tariff-impact">April Jobs Blow Past Expectations, But Tariff Storm May Be Brewing</a>
Photo: Shutterstock

Technicals

Stock Of The Day – Bullish Capitulation In Becton, Dickinson?

William Blair analyst Brian Weinstein downgrades Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) from Outperform to Market Perform.

William Blair Downgrades Becton Dickinson to Market Perform

Editor&#8217;s Note: The article has been udpated to correct the Stock Movers list.
Wall Street pushed higher in midday trading, with the S&amp;P 500 on track for its eighth consecutive gain — its longest winning streak since November 2023. The index rose about 1% to 5,560, fully recovering the losses sustained after former President Donald Trump announced <a href="https://www.benzinga.com/topic/tariffs">trade tariffs on April 2.</a>
Technology stocks led the rally, with the Nasdaq 100 climbing 1.5%. Strong and resilient corporate earnings continue to fuel investor appetite for risk, helping markets shrug off recent tariff concerns.
President Trump reassured investors, stating that progress on trade negotiations is going "very well" and that the timeline for the tax bill remains on schedule.
On the economic front, data continued to paint a weaker picture. After Wednesday's disappointing first-quarter GDP report, the ISM manufacturing PMI showed factory activity contracted for the second straight month in April. Meanwhile, price pressures surged at the fastest pace since June 2022, reflecting <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45139383/us-manufacturing-activity-contracts-in-april-as-tariffs-push-input-prices-toward-3-year-highs">inflationary effects from tariffs.</a>
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) was a standout gainer, soaring 8.60% after delivering a blowout quarter that beat expectations across the board, reinforcing its leadership in cloud and AI. The stock reached its highest level since late January.
Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) also topped estimates, with shares climbing more than 4%.
Sector-wise, technology outperformed, while health care lagged. Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) plunged over 9% after the pharmaceutical giant cut its 2025 guidance.
Crude oil erased early losses, rebounding to $58 per barrel after briefly dipping below $57. Gold slipped 2.2% to a two-week low.
The U.S. dollar strengthened to its highest level in over two weeks, bolstered by manufacturing surveys showing rising input costs tied to tariffs.
Treasury yields climbed for a second straight session, with the 10-year yield rising to 4.21%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) surged past the $97,000 mark, hitting its highest level in over two months.
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>% chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,853.70</td>
<td>+ 1.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,614.89</td>
<td>+ 0.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,971.76</td>
<td>+ 0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,802.25</td>
<td>+ 0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1% to $560.02.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.5% to $408.25.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 1.6% to $483.23.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.5% higher to $195.71.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 2.6%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 2.3%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
Stocks reacting to earnings reports included: Microsoft Corporation: up 8.30% Meta Platforms, Inc.: up 4.29% Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): &#8211; 9.88% Mastercard Incorporated&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>): -0.20% McDonald's Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>): -1.24% Linde plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>): -1.14% Qualcomm Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>): -8.28% KKR &amp; Co. Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>): up 1.19% The Southern Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>): up 0.22% Intercontinental Exchange, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>): up 1.83% KLA Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>): -2.43% CVS Health Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>): up 6.23% Equinix, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>): -0.16% Parker-Hannifin Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>): up 0.70% Air Products and Chemicals, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>): -0.09% Howmet Aerospace Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>): up 7.44% Carrier Global Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>): up 11% Aflac Incorporated&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>): -4% Public Storage&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>): -0.18% The Allstate Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>): -1.27% MetLife, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>): up 0.47% W.W. Grainger, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>): Up 2.14% Becton, Dickinson and Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>): -15.73% Quanta Services, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>): up 10.10% Exelon Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>): -0.33% Dominion Energy, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>): up 0.91%
Stocks slated to report earnings after the bell include Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>), Airbnb Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), Atlassian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>), Motorola Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>), EOG Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>), American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), Consolidated Edison Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>), Ingersoll Rand Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>), DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), Monolithic Power Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>), Ameren Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>), GoDaddy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>), Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>), MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>), Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>), Mohawk Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>), Camden Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPT#NYSE">CPT</a>) and Live Nation Entertainment Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>).
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45117801/apple-q2-earnings-preview-analysts-remain-bullish-with-caution-of-tariff-tornado-hitting-iphone">Apple Q2 Earnings Preview: Analysts Remain Bullish But Warn Of &#8216;Tariff Tornado&#8217; Hitting iPhone</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

Econ #s

$BTC

AMGN

SPDR Dow Jones Industrial Average ETF Trust

DXCM

EQIX

GDDY

KLAC

MPWR

MSTR

QCOM

TEAM

Wall Street Eyes 8th Positive Day As S&P 500 Recoups Tariff-Led Losses, Bitcoin Rallies To $97,000: What's Driving Markets Thursday? (CORRECTED)

Becton, Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) lowered its fiscal year 2025 guidance and provided an <a href="https://www.benzinga.com/pressreleases/25/05/n45128945/bd-reports-second-quarter-fiscal-2025-financial-results" target="_blank" rel="noopener">estimated tariff impact </a>on Thursday.
The medical device giant reported adjusted earnings per share of $3.35, up from $3.17 reported a year ago, beating the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of $3.28</a>.
The company reported first-quarter 2025 sales of $5.27 billion, up 4.5% year-over-year, missing the consensus of $5.35 billion.
&#8220;Amid a difficult operating environment impacting near-term organic revenue growth, our Q2 results reflect the strength of our business model and ability to exceed our earnings expectations through quality gross margin improvement,&#8221; said Tom Polen, chairman, CEO and president of BD.
 &#8220;Our BD Excellence operating system is driving continued margin expansion and increasing investment in our commercial organization and innovation, and we believe we are well positioned to accelerate growth as markets recover. As we take decisive mitigation actions to navigate the current macro environment, BD&#8217;s scale as the largest U.S. manufacturer of medical devices is a significant advantage for long-term value creation.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43443889/starboard-value-pushes-becton-dickinson-to-divest-life-sciences-unit" rel="noreferrer noopener">Activist Starboard Value Pushes Becton Dickinson To Divest Life Sciences Unit</a>
In February, BD shared its plan to separate its Biosciences and Diagnostic Solutions business from the rest of the company to enhance strategic focus, growth-oriented investments<a href="https://www.benzinga.com/25/02/43532512/becton-dickinson-outlines-intent-to-separate-biosciences-and-diagnostic-solutions-business-to-enhance-focus-drive-growth-q1-earnings-beat-street-view" target="_blank" rel="noreferrer noopener"> and capital allocation</a>.
Following the separation, New BD will be a pure-play medical technology company. It expects to drive concentrated investments in high-impact R&amp;D and disciplined capital allocation, including growth-accretive M&amp;A.
Medical segment sales increased 12.7% year over year to $2.76 billion, Life Sciences sales reached $1.25 billion, down 4.3%, and Interventional sales fell 2.2% to $1.26 billion.
Becton, Dickinson also announced its intention to invest $2.5 billion in U.S. manufacturing capacity over the next 5 years, further strengthening its position as the largest U.S. manufacturer of medical devices and its commitment to ensuring a resilient U.S. healthcare system.
Guidance:&nbsp;BD expects fiscal 2025 revenues of $21.8 billion&nbsp;and&nbsp;$21.9 billion&nbsp;compared to a consensus of $21.83 billion and its previously issued guidance of&nbsp;$21.7 billion&nbsp;to&nbsp;$21.9 billion, reflecting updated organic revenue growth guidance of 3.0% to 3.5% and an improvement in the estimated impact of foreign currency.
Before the impact of tariffs, the company expects adjusted diluted EPS to be consistent with its previously issued guidance of&nbsp;$14.30&nbsp;to&nbsp;$14.60, representing growth of 8.8% to 11.0%. It includes absorbing a headwind from translational foreign currency for approximately&nbsp;$0.05&nbsp;or 40 basis points for the full year.
Including an estimated tariff impact of approximately $0.25 for the fiscal year, the company now expects adjusted earnings of $14.06 to $14.34, compared to the consensus of $14.42.
The estimated tariff impact is based on current information and tariff programs announced as of April 30, not including announced tariff programs that are delayed or threatened, the company said in its Thursday press release.
Price Action:&nbsp;BDX stock is down 5.36% at $196 during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45135213/mcdonalds-q1-revenue-decline-34-as-war-in-the-middle-east-bites-stock-dips" target="_blank" rel="noreferrer noopener">Middle-East Tensions And Consumer Uncertainty Bites McDonald&#8217;s Q1 Revenue, Stock Slides</a></li>
</ul>
Photo: Shutterstock

Potential Tariff Bites Into Becton Dickinson 2025 Profit Outlook, Company Will Invest $2.5 Billion To Boost US Manufacturing

Becton Dickinson shares are trading lower after the company cut FY25 EPS guidance despite a sales outlook guidance raise. The company also missed Q2 revenue estimates.

Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) lowers FY2025 Adj EPS guidance from $14.30-$14.60 to $14.06-$14.34 vs $14.42 analyst estimate. Raises FY2025 sales outlook from $21.70 billion-$21.90 billion to $21.80 billion-$21.90 billion vs $21.83 billion estimate.

Becton Dickinson Lowers FY2025 Adj EPS Guidance from $14.30-$14.60 to $14.06-$14.34 vs $14.42 Est; Raises FY2025 Sales Guidance from $21.70B-$21.90B to $21.80B-$21.90B vs $21.83B Est

Becton, Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) reported quarterly earnings of $3.35 per share which beat the analyst consensus estimate of $3.28 by 2.13 percent. This is a 5.68 percent increase over earnings of $3.17 per share from the same period last year. The company reported quarterly sales of $5.27 billion which missed the analyst consensus estimate of $5.35 billion by 1.53 percent. This is a 4.50 percent increase over sales of $5.04 billion the same period last year.

Earnings Beats

Earnings Misses

Becton, Dickinson Q2 Adj. EPS $3.35 Beats $3.28 Estimate, Sales $5.27B Miss $5.35B Estimate

AAMI

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMWL

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

ECVT

ELME

Earnings Scheduled For May 1, 2025

Corporate insiders have not been impressively active so far in 2025. Despite a great deal of volatility, insiders have been held back by a rising wave of uncertainty. With the tariffs confusion lingering, it is tough for folks running corporations to get a handle on costs, profit margins, or economic conditions. While prices have retreated to a degree, it&#8217;s not like stocks are suddenly super cheap and attractive either. The S&amp;P 500 still trades with a PE ratio based on trailing earnings of 26 and a CAPE Ratio of 32.7. While off the highs of earlier this year, both are still extremely high by historical standards. Given the unattractive cocktail of valuation and uncertainty, insiders have pretty much kept their wallets in the desk drawer for much of the year.
This is another class of investor I track that thrives on uncertainty, and as a group, they have been very active so far this year. I am talking about activist investors, the more gentlemanly title for what were once known as corporate raiders. The Barclays Q1 2025 Review of Shareholder Activism reveals several important trends that can help us unlock opportunity.
Despite economic uncertainty and market volatility, activist campaigns have continued their upward trajectory. Global campaign activity reached 70 initiatives in Q1, representing a 17% increase year-over-year and running 25% above the four-year quarterly average. This suggests that periods of uncertainty often create fertile ground for activists to identify undervalued situations.
The most notable regional development is the resurgence of U.S. activism, which increased 43% year-over-year with 40 campaigns. After two years where American companies represented less than half of global targets, U.S. companies now account for 57% of global activist activity. Meanwhile, Japan continues to emerge as a significant battleground with 16 campaigns (up 45%), while European activity remains subdued with just 10 campaigns.
More importantly, the activists are scoring major wins. Companies like Honeywell (Ticker: HON), Becton Dickinson (Ticker: BDX), and Solventum (Ticker: SOLV) all announced significant break-ups or divestitures in Q1 following activist pressure.
The effectiveness of activist campaigns appears to be improving. The Barclays report identifies 51 board seats won in Q1, representing a 34% increase from the same period in 2024.
The King of the Activists this year is once again Elliott Management.
Elliott Management continues to lead the pack with four campaigns in Q1, including high-profile engagements at BP plc (Ticker: BP), where the company announced a refocus on its oil and gas business and a strategic review of its Castrol lubricants unit.
The campaign at BP has run into a snag in the form of lower oil and gas prices. As oil prices have pulled back in response to the tariff confusion, the share price of London-based oil and gas giant has fallen sharply. Elliott responded by upping its stake to over 5% of BP. That&#8217;s impressive given that BP has a $75 billion market cap.
Elliott wants management to drive the renewables business and cut spending by several billion dollars and has also outlined steps it feels BP should take that would get free cash flow to rise to $20 billion a year, well above the current $8 billion. Elliott has also suggested that leadership changes may be in order. The activist has met with many of BP&#8217;s largest shareholders to drum up support for its ideas.
At this point, even if Elliott does not win its campaign, the shares are attractive. Thanks to falling oil prices, the stock is trading at a depressed valuation and yields over 6%. A firming in energy prices could see the shares trade back up near the high of the year near $40. If Elliott does win the day and BP meets the cash flow targets, there is a good chance the shares will double or more in value.
BP is not Elliott&#8217;s only current campaign in the oil fields. In the spring of 2024, Elliott revealed a $1 billion stake in Phillips 66 (Ticker: PSX) and wasted no time firing off a blistering indictment of the company&#8217;s lackluster operational performance.
There has been a great deal of back and forth, but Elliott has not been appeased and has moved forward with a proxy fight. The activist is seeking four seats on the board of the refiner. They recently sent a letter to Phillips shareholders that said, &#8220;Investors&#8217; patience has been punished, and a new lineup on the board is necessary to reverse the company&#8217;s long-term underperformance and improve its poor corporate governance practices.&#8221;
Phillips fired back, sending its own letter that pointed out, &#8220;Since our formation in 2012, we have returned more than $43 billion to shareholders through dividends and share repurchases. We have grown our dividend at a 15% Compound Annual Growth Rate (&#8216;CAGR&#8217;). The dividend we pay to our shareholders has grown every single year since we have been a publicly-traded company – even through troughs in commodity cycles and periods of economic disruption. Not many energy companies can say the same.&#8221;
This is another potential win-win for investors. The stock is cheap, and management just raised the dividend to yield 4.5%. Improved economic and market conditions could easily lead to a huge bump in the price of the stock. If Elliott wins the proxy battle and its changes are effective, the upside potential is again over 100%.
In the case of both BP and Phillips 66, investors get paid handsomely to wait for the battle to be played out.

Opinion

SOLV

Alpha Buying: Big Oil Becomes Ground Zero for Activist Investing in 2025

4 analysts have expressed a variety of opinions on Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Becton Dickinson, revealing an average target of $270.0, a high estimate of $280.00, and a low estimate of $260.00. This current average represents a 2.88% decrease from the previous average price target of $278.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1745442035_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Becton Dickinson by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $260.00&#x7C;$280.00 &#x7C; 
&#x7C;Travis Steed &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $261.00&#x7C;$279.00 &#x7C; 
&#x7C;Travis Steed &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $279.00&#x7C;$278.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $280.00&#x7C;$275.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Becton Dickinson. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Becton Dickinson compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Becton Dickinson's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Becton Dickinson's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Becton Dickinson analyst ratings.</a>
<h2>About Becton Dickinson</h2>
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
<h3>Breaking Down Becton Dickinson's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Becton Dickinson's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 9.82%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Becton Dickinson's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 5.86%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Becton Dickinson's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.19%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Becton Dickinson's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.54%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.74.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For Becton Dickinson

Piper Sandler analyst Jason Bednar maintains Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) with a Overweight and lowers the price target from $280 to $260.

Piper Sandler Maintains Overweight on Becton Dickinson, Lowers Price Target to $260

Phasix&#x2122; ST Umbilical Hernia Patch Leverages Same Surgical Technique as Permanent Mesh Procedures&nbsp;
FRANKLIN LAKES, N.J., April 23, 2025 /PRNewswire/ --&nbsp;BD (Becton, Dickinson and Company) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), a leading global medical technology company, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) and the commercial launch of Phasix&#x2122; ST Umbilical Hernia Patch, the first and only fully absorbable hernia patch on the market designed specifically for umbilical hernias. &nbsp;

BD Announces 510(k) Clearance From FDA And Commercial Launch Of Phasix ST Umbilical Hernia Patch

Press Releases

BD to Present at Investor Healthcare Conferences

BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery

BD Names Gregory J. Hayes to Board of Directors

BD Named One of America's Most Innovative Companies by Fortune

BD to Announce Financial Results for its Second Quarter of Fiscal 2025

BD Launches Next Generation Hemodynamic Monitoring Solution Providing Clinicians with AI-Driven Clinical Decision Support

BD Launches Industry-First Bioabsorbable Mesh Designed for Umbilical Hernia Repair

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
04:01 PMFeb 18, 2025	PUT	$245.00	Feb 21, 2025	-74	2150	800	69	3100	TRADE	BEARISH
04:01 PMFeb 18, 2025	PUT	$240.00	Feb 21, 2025	-74	2150	800	60	3579	TRADE	BEARISH

Comments

Becton Dickinson

Unusual Options Activity for

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO